Inflammatory biomarkers associated with obesity and insulin resistance: A focus on lipocalin-2 and adipocyte fatty acid-binding protein

Expert Review of Endocrinology and Metabolism

Volumn 3, Issue 1, 2008, Pages 29-41

  Hoo, Ruby L C ^a   Yeung, Dennis C Y ^a   Lam, Karen S L ^a   Xu, Aimin ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Adipocyte fatty acid binding protein; Adipokine; Cardiovascular disease; Diabetes; Inflammation; Lipocalin 2; Obesity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTE FATTY ACID BINDING PROTEIN; ADIPOCYTE FATTY ACID BINDING PROTEIN INHIBITOR; ADIPOCYTOKINE; ANTIINFLAMMATORY AGENT; BINDING PROTEIN; C REACTIVE PROTEIN; CHEMOKINE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOCALIN 2 PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; SALICYLIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETOGENESIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; FATTY ACID METABOLISM; GENE EXPRESSION PROFILING; GENETIC RISK; GENETIC VARIABILITY; HEPATITIS; HIGH RISK PATIENT; HUMAN; INFECTION RISK; INFLAMMATION; INSULIN RESISTANCE; LIPID DIET; MACROPHAGE ACTIVATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIODONTITIS; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; STRUCTURE ANALYSIS;

EID: 37549058420     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/17446651.3.1.29     Document Type: Review

References (132)

1. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterology 132, 2087-2102 (2007).
2. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 132, 2208-2225 (2007).
3. Chen H. Cellular inflammatory responses: novel insights for obesity and insulin resistance. Pharmacol. Res. 22, 22 (2006).
4. Shoelson,SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 132, 2169-2180 (2007).
5. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40, 1286-1292 (1997).
6. Hanley AJ, Williams K, Festa A et al. Elevations in markers of liver injury and risk of Type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 53, 2623-2632(2004).
7. Tan KC, War NM, Tam SC, Janus ED, Lam TH, Lam KS. C-reactive protein predicts the deterioration of glycemia in Chinese subjects with impaired glucose tolerance. Diabetes Care 26, 2323-2328 (2003).
8. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108, 2957-2963 (2003).
9. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet 366, 1809-1820 (2005).
10. Bahtiyar G, Shin JJ, Aytaman A, Sowers JR, McFarlane SI. Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights. Curr. Diab. Rep. 4, 194-198 (2004).
11. Yuan M, Konstantopoulos N, Lee J et al Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKβ. Science 293, 1673-1677 (2001).
12. Freeman DJ, Norrie J, Sattar N et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103, 357-362 (2001).
13. Muhlestein JB, May HT, Jensen JR et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J. Am. Coll. Cardiol. 48, 396-401 (2006).
14. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 369, 1208-1219 (2007).
15. Mohanty P, Aljada A, Ghanim H et al. Evidence for a potent antiinflammatory effect of rosightazone. J. Clin. Endocrinol. Metab. 89, 2728-2735 (2004).
16. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259, 87-91 (1993).
17. Hotamisligil GS. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes 54(Suppl. 2), S73-S78 (2005).
18. Kaneto H, Nakatani Y, Miyatsuka T et al. Possible novel therapy for diabetes with cell-permeable JNK-irihibitory peptide. Nat. Med. 10, 1128-1132 (2004).
19. Arkan MC, Hevener AL, Greten FR et al. IKK-β links inflammation to obesity-induced insulin resistance. Nat. Med. 11, 191-198 (2005).
20. Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol. Cell Biol. 24, 5434-5446 (2004).
21. Shi H, Tzameli I, Bjorbaek C, Flier JS. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J Biol. Chem. 279, 34733-34740 (2004).
22. Howard JK, Cave BJ, Oksanen LJ, Tzameli I, Bjorbaek C, Flier JS. Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3. Nat. Med. 10, 734-738 (2004).
23. Steinberg GR, Michell BJ, van Denderen BJ et al. Tumor necrosis factor α-induced skeletal muscle insulin resistance involves suppression of AMP-ldnase signaling. Cell Metab. 4, 465-474 (2006).
24. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 6, 772-783 (2006).
25. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin. Immunol. 115, 911-919 (2005).
26. Weisberg SP, McCann D, Desai M Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin. Invest. 112, 1796-1808 (2003).
27. Xu H, Barnes GT, Yang Q et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112, 1821-1830 (2003).
28. Curat CA, Miranville A, Sengenes C et al. From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes 53, 1285-1292 (2004).
29. Cinti S, Mitchell G, Barbatelli G et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 46, 2347-2355 (2005).
30. Fujiwara N, Kobayashi K. Macrophages in inflammation. Curr. Drug Targets Inflamm. Allergy 4, 281-286 (2005).
31. Charriere G, Cousin B, Arnaud E et al. Preadipocyte conversion to macrophage. Evidence of plasticity. J. Biol. Chem. 278, 9850-9855 (2003).
32. Kamei N, Tobe K, Suzuki R et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J. Biol. Chem. 281, 26602-26614 (2006).
33. Kanda H, Tateya S, Tamori Y et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest. 116, 1494-1505 (2006).
34. Ye J, Gao Z, Yin J, He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am. J. Physiol. Endocrinol. Metab. (2007).
35. Pou KM, Massaro JM, Hoffmann U et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation 116, 1234-1241 (2007).
36. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257, 79-83 (1999).
37. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J. Biol. Chem. 268, 10425-10432 (1993).
38. Goetz DH, Willie ST, Armen RS, Bratt T, Borregaard N, Strong RK. Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry 39, 1935-1941 (2000).
39. Bratt T, Ohlson S, Borregaard N. Interactions between neutrophil gelatinase-associated lipocalin and natural lipophilic ligands. Biochim. Biophys. Acta 1472, 262-269 (1999).
40. Kjeldsen L, Cowland JB, Borregaard N. Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse. Biochim. Biophys. Acta 1482, 272-283 (2000).
41. Flower DR, North AC, Sansom CE. The lipocalin protein family: structural and sequence overview. Biochim. Biophys. Acta 1482, 9-24 (2000).
42. Chu ST, Huang HL, Chen JM, Chen YH. Demonstration of a glycoprotein derived from the 24p3 gene in mouse uterine luminal fluid. Biochem. J. 316 (Pt 2), 545-550 (1996).
43. Rudd PM, Mattu TS, Masure S et al. Glycosylation of natural human neutrophil gelatinase B and neutrophil gelatinase B-associated lipocalin. Biochemistry 38, 13937-13950 (1999).
44. Hraba-Renevey S, Turler H, Kress M, Salomon C, Weil R. SV40-induced expression of mouse gene 24p3 involves a post-transcriptional mechanism. Oncogene 4, 601-608 (1989).
45. Flo TH, Smith KD, Sato S et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 432, 917-921 (2004).
46. Fischbach MA, Lin H, Zhou L et al. The pathogen-associated iroA gene cluster mediates bacterial evasion of lipocalin 2. Proc. Natl Acad. Sci. USA 103, 16502-16507 (2006).
47. Mori K, Lee HT, Rapoport D et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J. Clin. Invest. 115, 610-621 (2005).
48. Berger T, Togawa A, Duncan GS et al. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc. Natl Acad. Sci. USA 103, 1834-1839 (2006).
49. Playford RJ, Belo A, Poulsom R et al. Effects of mouse and human lipocalin homologues 24p3/lcn2 and neutrophil gelatinase-associated lipocalin on gastrointestinal mucosal integrity and repair. Gastroenterology 131, 809-817 (2006).
50. Tong Z, Wu X, Kehrer JP, Increased expression of the lipocalin 24p3 as an apoptotic mechanism for MK886. Biochem. J. 372, 203-210 (2003).
51. Tong Z, Wu X, Ovcharenko D, Zhu J, Chen CS, Kehrer JP. Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem. J. 391, 441-448 (2005).
52. Hvidberg V, Jacobsen C, Strong RK, Cowland JB, Moestrup SK, Borregaard N. The endocytic receptor megatin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and mediates its cellular uptake. FEBS Lett. 579, 773-777 (2005).
53. Devireddy LR, Gazin C, Zhu X, Green MR. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 123, 1293-1305 (2005).
54. Cowland JB, Sorensen OE, Sehested M, Borregaard N. Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 β, but not by TNF-α. J. Immunol. 171, 6630-6639 (2003).
55. Meheus LA, Fransen LM, Raymackers JG et al. Identification by microsequencing of lipopolysaccharide-induced proteins secreted by mouse macrophages. J. Immunol. 151, 1535-1547 (1993).
56. Pawluczyk IZ, Furness PN, Harris KP. Macrophage-induced rat mesangial cell expression of the 24p3-like protein α-2-microglobulin-related protein. Biochim. Biophys. Acta 1645, 218-227 (2003).
57. Vizzardelli C, Pavelka N, Luchini A et al. Effects of dexamethazone on LPS-induced activation and migration of mouse dendritic cells revealed by a genome-wide transcriptional analysis. Eur. J. Immunol. 36, 1504-1515 (2006).
58. Bu DX, Hemdahl AL, Gabrielsen A et al. Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-κB. Am. J. Pathol. 169, 2245-2253 (2006).
59. Cowland JB, Muta T, Borregaard N. IL-1β-specific up-regulation of neutrophil gelatinase-associated lipocalin is controlled by IκB-ζ. J. Immunol. 176, 5559-5566 (2006).
60. Draper DW, Bethea HN, He YW. Toll-like receptor 2-dependent and -independent activation of macrophages by group B streptococci. Immunol. Lett. 102, 202-214 (2006).
61. Anwaar I, Gottsater A. Ohlsson K, Mattiasson I, Lindgarde F. Increasing levels of leukocyte-derived inflammatory mediators in plasma and cAMP in platelets during fbilow-up after acute cerebral ischemia. Cerebrovasc. Dis. 8, 310-317 (1998).
62. Falke P, Elneihoum AM, Ohlsson K. Leukocyte activation: relation to cardiovascular mortality after cerebrovascular ischemia. Cerebrovasc. Dis. 10, 97-101 (2000).
63. Mishra J, Dent C, Tarabishi R et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365, 1231-1238 (2005).
64. Schaub S, Mayr M, Honger G et al. Detection of subclinical tubular injury after renal transplantation: comparison of urine protein analysis with allograft histopathology. Transplantation 84, 104-112 (2007).
65. Trachtman H, Christen E, Cnaan A et al. Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury. Pediatr. Nephrol. 21, 989-994 (2006).
66. Liu Q, Nilsen-Hamilton, M. Identification of a new acute phase protein. J. Biol. Chem. 270, 22565-22570 (1995).
67. Xu S, Venge P. Lipocalins as biochemical markers of disease. Biochim. Biophys. Acta 1482, 298-307 (2000).
68. Shen F, Ruddy MJ, Plamondon P, Gaffen SL. Cytokines link osteoblasts and inflammation: microarray analysis of interleukin-17- and TNF-α-induced genes in bone cells. J. Leukoc. Biol. 77, 388-399 (2005).
69. Aigner F, Maier HT, Schwelberger HG et al. Lipocalin-2 regulates the inflammatory response during ischemia and reperfusion of the transplanted heart. Am. J. Transplant. 7, 779-788 (2007).
70. Hemdahl AL, Gabrielsen A, Zhu C et al. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb. Vasc. Biol. 26, 136-142 (2006).
71. Faber K, Axler O, Dahlback B, Nielsen LB. Characterization of apoM in normal and genetically modified mice. J. Lipid Res. 45, 1272-1278 (2004).
72. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J. Biol. Chem. 276, 37258-37265 (2001).
73. Elneihoum AM, Falke P, Axelsson L, Lundberg E, Lindgarde F, Ohlsson K. Leukocyte activation detected by increased plasma levels of inflammatory mediators in patients with ischemic cerebrovascular diseases. Stroke 27, 1734-1738 (1996).
74. Elneihoum AM, Falke P, Hedblad B, Lindgarde F, Ohlsson K. Leukocyte activation in atherosclerosis: correlation with risk factors. Atherosclerosis 131, 79-84 (1997).
75. Lin Y, Rajala MW, Berger JP, Moller DE, Barzilai N, Scherer PE. Hyperglycemia-induced production of acute phase reactants in adipose tissue. J. Biol. Chem. 276, 42077-42083 (2001).
76. Kratchmarova I, Kalume DE, Blagoev B et al. A proteomic approach for identification of secreted proteins during the differentiation of 3T3-L1 preadipocytes to adipocytes. Mol Cell Proteomics 1, 213-222 (2002).
77. Baudry A, Yang ZZ, Hemmings BA. PKBα is required for adipose differentiation of mouse embryonic fibroblasts. J. Cell. Sci. 119, 889-897 (2006).
78. Wang Y, Lam KS, Kraegen EW et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin. Chem. 53, 34-41 (2007).
79. Yan QW, Yang Q, Mody N et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes 56(10), 2533-2540 (2007).
80. Jayaraman A, Roberts KA, Yoon J et al. Identification of neutrophil gelatinase-associated lipocalin (NGAL) as a discriminatory marker of the hepatocyte-secreted protein response to IL-1β: a proteomic analysis. Biotechnol. Bioeng. 91, 502-515 (2005).
81. Sweetser DA, Birkenmeier EH, Klisak IJ et al. The human and rodent intestinal fatty acid binding protein genes. A comparative analysis of their structure, expression, and linkage relationships. J. Biol. Chem. 262, 16060-16071 (1987).
82. Boord JB, Fazio S, Linton MF. Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis. Curr. Opin. Lipidol. 13, 141-147 (2002).
83. Bernlohr DA Simpson MA, Hertzel AV et al. Intracellular lipid-binding proteins and their genes. Annu. Rev. Nutr. 17, 277-303 (1997).
84. Flower DR. The lipocalin protein family: structure and function. Biochem. J. 318(Pt 1), 1-14 (1996).
85. Bonen A, Luiken JJ, Liu S et al. Palmitate transport and fatty acid transporters in red and white muscles. Am. J. Physiol. 275, E471-E478 (1998).
86. Ho SY, Storch J. Common mechanisms of monoacylglycerol and fatty acid uptake by human intestinal Caco-2 cells. Am. J. Physiol. Cell. Physiol. 281, C1106-1117 (2001).
87. Makowski L, Hotamisligil GS. Fatty acid binding proteins - the evolutionary crossroads of inflammatory and metabolic responses. J. Nutr. 134, S2464-S2468 (2004).
88. Kazemi MR, McDonald CM, Shigenaga JK, Grunfeld C, Feingold KR. Adipocyte fatty acid-binding protein expression and lipid accumulation are increased during activation of murine macrophages by Toll-like receptor agonists. Arterioscler. Thromb. Vasc. Biol. 25, 1220-1224 (2005).
89. Pelton PD, Zhou L, Demarest KT, Burris TP. PPAR activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes. Biochem. Biophys. Res. Commun. 261, 456-458 (1999).
90. Matarese V, Bernlohr DA. Purification of murine adipocyte lipid-binding protein. Characterization as a fatty acid- and retinoic acid-binding protein. J. Biol. Chem. 263, 14544-14551 (1988).
91. Veerkamp JH, van Moerkerk HT, Prinsen CF, van Kuppevelt TH. Structural and functional studies on different human FABP types. Mol. Cell. Biochem. 192, 137-142 (1999).
92. Simpson MA, LiCata VJ, Ribarik Coe N, Bernlohr DA. Biochemical and biophysical analysis of the intracellular lipid binding proteins of adipocytes. Mol. Cell. Biochem. 192, 33-40 (1999).
93. Amri EZ, Bertrand B, Ailhaud G, Grimaldi P. Regulation of adipose cell differentiation. I. Fatty acids are inducers of the aP2 gene expression. J. Lipid Res. 32, 1449-1456 (1991).
94. Distel RJ, Robinson GS, Spiegelman BM. Fatty acid regulation of gene expression. Transcriptional and post-transcriptional mechanisms. J. Biol. Chem. 267, 5937-5941 (1992).
95. Duplus E, Forest C. Is there a single mechanism for fatty acid regulation of gene transcription? Biochem. Pharmacol. 64, 893-901 (2002).
96. Schachtrup C, Emmler T, Bleck B, Sandqvist A, Spener E Functional analysis of peroxisome-prolifefator-responsive element motifs in genes of fatty acid-binding proteins. Biochem. J. 382, 239-245 (2004).
97. Liu J, Farmer SR. Regulating the balance between peroxisome proliferator-activated receptor γ and β-catenin signaling during adipogenesis. A glycogen synthase kinase 3β phosphorylation-defective mutant of β-catenin inhibits expression of a subset of adipogenic genes. J. Biol. Chem. 279, 45020-45027 (2004).
98. Coe NR, Simpson MA, Bernlohr DA. Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. J. Lipid Res. 40, 967-972 (1999).
99. /- mice. Diabetes 48, 1987-1994 (1999).
100. Shen WJ, Sridhar K, Bernlohr DA, Kraemer FB. Interaction of rat hormone-sensitive lipase with adipocyte lipid-binding protein. Proc. Natl Acad. Sci. USA 96, 5528-5532 (1999).
101. Shen WJ, Liang Y, Hong R et al. Characterization of the functional interaction of adipocyte lipid-binding protein with hormone-sensitive lipase. J. Biol. Chem. 276, 49443-49448 (2001).
102. Fu Y, Luo L, Luo N, Garvey WT. Lipid metabolism mediated by adipocyte lipid binding protein (ALBP/aP2) gene expression in human THP-1 macrophages. Atherosclerosis 188, 102-111 (2006).
103. Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 274, 1377-1379 (1996).
104. Uysal KT, Scheja L, Wiesbrock SM, Bonner-Weir S, Hotamisligil GS. Improved glucose and lipid metabolism in genetically obese in ice lacking aP2. Endocrinology 141, 3388-3396 (2000).
105. Krieg R Feil S, Furstenberger G, Bowden GT. Tumor-specific overexpression of a novel keratinocyte lipid-binding protein. Identification and characterization of a cloned sequence activated during multistage carcinogenesis in mouse skin. J. Biol. Chem. 268, 17362-17369 (1993).
106. Maeda K, Cao H, Kono K et al. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab. 1, 107-119 (2005).
107. Sulsky R, Magnin DR, Huang Y et al. Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP). Bioorg. Med. Chem. Lett. 17, 3511-3515 (2007).
108. Furuhashi M, Tuncman G, Gorgun CZ et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 447, 959-965 (2007).
109. Makowski L, Boord JB, Maeda K et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat. Med. 7, 699-705 (2001).
110. Boord JB, Maeda K, Makowski L et al. Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 22, 1686-1691 (2002).
111. Boord JB, Maeda K, Makowski L et al. Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation 110, 1492-1498 (2004).
112. Layne MD, Patel A, Chen YH et al. Role of macrophage-expressed adipocyte fatty acid binding protein in the development of accelerated atherosclerosis in hypercholesterolemic mice. FASEB J. 15, 2733-2735 (2001).
113. Fu Y, Luo N, Lopes-Virella MF. Oxidized LDL induces the expression of ALBP/aP2 mRNA and protein in human THP-1 macrophages. J. Lipid Res. 41, 2017-2023 (2000).
114. Llaverias G, Noe V, Penuelas S et al. Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages. Biochem. Biophys. Res. Commun. 318, 265-274 (2004).
115. Fu Y, Luo N, Lopes-Virella MF, Garvey WT. The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages. Atherosclerosis 165, 259-269 (2002).
116. Makowski L, Brittingham KC, Reynolds JM, Suttles J, Hotamisligil GS. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor γ and IκB kinase activities. J. Mol. Chem. 280, 12888-12895 (2005).
117. Shum BO, Mackay CR, Gorgun CZ et al. The adipocyte fatty acid-binding protein aP2 is required in allergic airway inflammation. J. Clin. Invest. 116, 2183-2192 (2006).
118. Reynolds JM, Liu Q, Brittingham KC et al. Deficiency of fatty acid-binding proteins in mice confers protection from development of experimental autoimmune encephalomyelitis. J. Immunol. 179, 313-321 (2007).
119. Xu A, Wang Y, Xu JY et al. Adipocyte fatty acid binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin. Chem. 52, 405-413 (2006).
120. Stejskal D, Karpisek M. Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome? Eur. J. Clin. Invest. 36, 621-625 (2006).
121. Mohlig M, Weickert MO, Ghadamgadai E et al. Adipocyte fatty acid-binding protein is associated with markers of obesity, but is an unlikely link between obesity, insulin resistance, and hyperandrogenism in polycystic ovary syndrome women. Eur. J. Endocrinol. 157, 195-200 (2007).
122. Haider DG, Schindler K, Bohdjalian A et al. Plasma adipocyte and epidermal fatty acid binding protein is reduced after weight loss in obesity. Diabetes Obes. Metab. 9, 761-763 (2007).
123. Xu A, Tso AW, Cheting BM et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 115, 1537-1543 (2007).
124. Tso AW, Xu A, Sham PC et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of Type 2 diabetes - a 10-year prospective study in Chinese. Diabetes Care 30(10), 2667-2672 (2007).
125. Yeung DC, Xu A, Cheung CW et al. Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27, 1796-1802 (2007).
126. Mora S, Blumenthal RS, Yanek LR et al. Elevated C-reactive protein in high-risk asymptomatic individuals is strongly associated with the metabolic syndrome. J. Am. Coll. Cardiol. 41, A292 (2003).
127. Ajuwon KM, Spurlock ME. Adiponectin inhibits LPS-induced NF-κB activation and IL-6 production and increases PPAR2 expression in adipocytes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288, R1220-R1225 (2005).
128. Hertzel A, Smith L, Berg A et al. Lipid metabolism and adipokine levels in fatty acid-binding protein null and transgenic mice. Am. J. Physiol. Endocrinol. Metab. 290, E814-E823 (2006).
129. Damcott CM, Moffett SP, Feingold E et al. Genetic variation in fatty acid-binding protein-4 and peroxisome proliferator-activated receptor interactively influence insulin sensitivity and body composition in males. Metabolism 53, 303-309 (2004).
130. Tuncman G, Erbay E, Hom X et al. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, Type 2 diabetes, and cardiovascular disease. Proc. Natl Acad. Sci. USA 103, 6970-6975 (2006).
131. Yang Q, Graham TE, Mody N et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and Type 2 diabetes. Nature 436, 356-362 (2005).
132. Graham TE, Yang Q, Bluher M et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N. Engl. J. Med. 354, 2552-2563 (2006).